EXHIBIT 10.4

Portions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of
1934. Such omissions are designated as ***.

AMENDMENT NO. 4 TO

LICENSE AGREEMENT

DATED AS OF APRIL 13, 2002

BY AND BETWEEN

UNIGENE LABORATORIES,
INC.

AND

SMITHKLINE BEECHAM CORPORATION

This Amendment No. 4 (Amendment No. 4) dated as of May 27, 2004
(Amendment Date), to the License Agreement, entered into as of the 13th of April, 2002 and amended on January 14, 2003 and October 14, 2003 (referred to hereinafter as the Agreement), by and between Unigene
Laboratories, Inc. (Unigene), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline company (GSK), a Pennsylvania corporation.

WHEREAS, GSK and Unigene entered into the Agreement to provide for the license grant by Unigene to GSK of certain Licensed Technology (as defined in the
Agreement) to discover, develop, make, have made, market, sell and import certain Licensed Products (as defined in the Agreement) throughout the world under the Unigene Patent Rights (as defined in the Agreement) and Unigene Know-How (as defined in
the Agreement); and

WHEREAS, GSK and Unigene have also entered into a Phase I Clinical Manufacture and Supply Agreement dated
November 20, 2002 (the Phase I Agreement); and

WHEREAS, pursuant to Section 11.10 of the Agreement, the Parties to
the Agreement may, by written instruments specifically referring to and executed in the same manner as the Agreement, amend the Agreement; and

WHEREAS, the Parties hereto desire to amend the Agreement as provided herein, and any capitalized terms used herein shall have the meaning set forth in the Agreement;

NOW THEREFORE, for and in consideration of the premises and the mutual promises and benefits contained herein, GSK and Unigene hereby agree as follows:

1. Appendix B to the Agreement (the Work Plan) is hereby amended to add the activities regarding PTH*** set forth in Appendix A to this Amendment
No. 4 at the FTE cost set forth in Appendix A to this Amendment No. 4.



---

2. Appendix C to the Agreement (Unigene Know-How and Technology Transfer) is hereby amended to add the technology and
know-how regarding PTH*** set forth in Appendix B to this Amendment No. 4.

3. Section 4.5 of the Agreement shall be amended and restated in its
entirety to read:

Unigene Data Transfer. Immediately after the Effective Date (or with respect to PTH *** Unigene Know-How,
immediately after the Amendment Date of Amendment No. 4 to this Agreement, as applicable), Unigene shall use its reasonable best efforts to promptly transfer, or cause to be transferred to GSK, a copy of Unigene Know-How relating to PTH and
the Licensed Product, including manufacture of API, to enable GSK to carry out its responsibilities under this Agreement. Such data shall include, at a minimum, the information set forth in Appendix C to this Agreement, attached hereto and
incorporated herein.

4. Appendix A to Amendment No. 2 to the Agreement, dated October 14, 2003, is hereby amended to include:



|              |  |                         
|------------- |  | ------------------------
|Type          |  | Designation (Designator)
|*** Cell Bank |  | *** (Unigene)           
|              | 
|*** Cell Bank |  | *** (Unigene)           
|              | 
|***           |  | *** (Unigene)           

5. Except as specifically provided herein, all other terms and conditions of the Agreement shall remain in full
force and effect, and this Amendment No. 4 to the Agreement shall not be construed to amend or waive any provisions of the Agreement except as specifically set forth above.

6. This Amendment No. 4 to the Agreement, and the rights and obligations of the Parties hereunder, shall be construed in accordance with, and governed by the laws of the Commonwealth of Pennsylvania (without
regard to its conflict of laws principles).

7. This Amendment No. 4 may be executed in two (2) or more counterparts, each of which shall be
deemed an original but all of which together shall constitute one and the same instrument.

8. This Amendment No. 4 shall inure to the benefit of and
be binding upon the GSK and Unigene and their respective successors, heirs and assigns.



---

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment No. 4 to be duly executed by their authorized
representatives as of the Amendment Date.



|                           |  |                          |  |                                                           |  |        |  |                           
|-------------------------- |  | ------------------------ |  | --------------------------------------------------------- |  | ------ |  | --------------------------
|UNIGENE LABORATORIES, INC. |  |                          |  | SMITHKLINE BEECHAM CORPORATION, a GlaxoSmithKline Company
|                           |  |                          |  |                                                          
|By:                        |  | /s/ Ronald S. Levy       |  |                                                           |  | By:    |  | /s/ Donald F. Parman      
|Name:                      |  | Ronald S. Levy           |  |                                                           |  | Name:  |  | Donald F. Parman          
|Title:                     |  | Executive Vice President |  |                                                           |  | Title: |  | Vice President & Secretary



---

Appendix A

Summary of Unigene R&D FTE/Activities for PTH***



|                                                                                                                                                                                                                                                                                                                                                                                                                                    |  |                 |    |  |           |    |  |            |   
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | --------------- | -- |  | --------- | -- |  | ---------- | --
|Activity Description                                                                                                                                                                                                                                                                                                                                                                                                                |  | EstimatedPeriod |    |  | Duration* |    |  | UnigeneFTE |   
|FERMENTATION and PURIFICATION: Unigene to prepare
Seed Bank of *** PTH*** and perform preliminary characterization tests to test for suitability of this cell bank. The following tests will be performed: Viable cell count, Kanamycin resistance, Verification of genotype, DNA sequencing of PTH insert.
Vials of the Seed Bank will be transferred to GSK for preparation and characterization of Master and Working Cell Banks |  | *               | ** |  | *         | ** |  | *          | **
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |  |                 |   
|FERMENTATION and PURIFICATION: Unigene to
optimize fermentation of *** at the 1 liter scale to develop consistent process and optimize productivity                                                                                                                                                                                                                                                                                 |  | *               | ** |  | *         | ** |  | *          | **
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |  |                 |   
|FERMENTATION and PURIFICATION: Unigene to
optimize and scale up purification and amidation steps for PTH***                                                                                                                                                                                                                                                                                                                         |  | *               | ** |  | *         | ** |  | *          | **
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |  |                 |   
|FERMENTATION and PURIFICATION: Unigene to carry
out 3 fermentations at the 30 liter scale for *** and purify and amidate material from these fermentations. Unigene will provide 20 grams of non-GMP PTH *** from these purifications                                                                                                                                                                                               |  | *               | ** |  | *         | ** |  | *          | **
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |  |                 |   
|PTH *** IMMUNOASSAY DEVELOPMENT: Optimize *** for
the detection of PTH***. The *** will be the same *** antibody currently used for PTH***. The *** will be a *** that has already been prepared by Unigene that has a high titer binding for PTH***. If successful, an additional *** will be raised under
contract at *** for an approximate cost of ***                                                                          |  | *               | ** |  | *         | ** |  | *          | **
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |  |                 |   
|PTH *** IMMUNOASSAY DEVELOPMENT: Epitope mapping
studies for *** PTH *** antibodies. Peptides for epitope mapping will be obtained by custom syntheses from external sources for an approximate cost of ***                                                                                                                                                                                                                         |  | *               | ** |  | *         | ** |  | *          | **

FTE Cost ***

Total
cost for Fermentation and Purification activities (including cost of 20g non-GMP material: ***



---

Total cost of Immunoassay Development activities (to include *** purchase of peptides for *** mapping and *** for cost of
immunization at ***



---

Appendix B

Unigene Know-How and Technology Transfer with Respect to PTH***



|1. | All experimental details, data and documentation for pharmacology studies in any animal species with oral, subcutaneous, and IV ***PTH*** alone or compared to other peptide(s)
performed by Unigene or third party laboratories.
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|2. | Host cell, plasmids, documentation and experimental details for the preparation of ***PTH***, transformation and growth of cell strains expressing ***PTH***.
|-- | -------------------------------------------------------------------------------------------------------------------------------------------------------------



|3. | The current optimal cell strain for producing ***PTH*** and any other ***PTH*** strains deemed to be of interest to GSK.
|-- | ------------------------------------------------------------------------------------------------------------------------



|4. | The current optimal cell line for producing the amidating enzyme and any other cell lines expressing the amidating enzyme deemed to be of interest to GSK
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------



|5. | All reagents, documentation and experimental details for expression, isolation and purification of ***PTH***.
|-- | -------------------------------------------------------------------------------------------------------------



|6. | All analytical experimental details, reagents, data and documentation for characterization of ***PTH***.
|-- | --------------------------------------------------------------------------------------------------------



|7. | All reagents, documentation and experimental details for the preparation and purification of polyclonal antibodies against ***PTH***.
|-- | -------------------------------------------------------------------------------------------------------------------------------------



|8. | All analytical experimental details, data and documentation for characterization of the polyclonal ***PTH*** antibodies.
|-- | ------------------------------------------------------------------------------------------------------------------------



|9. | All experimental details, reagents, data and reports on ***PTH*** immunoassay development activity.
|-- | ---------------------------------------------------------------------------------------------------



|10. | All reagents, documentation and experimental details for running the current immunoassay against ***PTH***.
|--- | -----------------------------------------------------------------------------------------------------------



|11. | All experimental details, data and documentation for pharmacokinetic studies in any animal species with oral, subcutaneousand IV ***PTH*** performed by Unigene or third party
laboratories.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------